The researchers found that concurrent use of amiodarone, fluconazole, rifampin, and phenytoin was associated with increased risk of major bleeding compared with the use of NOACs alone.
VTE and cancer are the result of inflammation and immunological dysfunctions associated with RA.
Researchers found a strong association between VTE and height using sibling pair analysis.
Researchers observed a linear increase in cancer prevalence with age, with a 7-fold higher prevalence in patients older than 50 years of age.
Fondaparinux and rivaroxaban were associated with increased risk of major bleeding in patients who underwent total hip or knee arthroplasty.
Researchers found a paradoxical increase in thromboembolism risk in low-weight patients with atrial fibrillation and VTE who were treated with direct oral anticoagulants.
Researchers developed a protocol to demonstrate the efficacy of rivaroxaban in lowering the risk of venous thromboembolism among orthopedic joint surgery patients.
The therapy may be cost-effective for patients with a predicted 1-year VTE risk of 17.5% or more.
Results showed that mean induction times, analyzed in 170 patients, were 12.87 days in the HIV-infected patients and 11.19 days in the HIV-uninfected patients.
Surgical pulmonary embolectomy for peripheral distribution of thrombus demonstrated positive outcomes in patients with either CPE or PPE.
